Search
reslizumab (Cinqair)
Indications:
- maintenance treatment of severe asthma in patients >= 18 years of age (for use in conjuction with other agents)
- history of severe asthma exacerbations despite appropriate asthma therapy
Dosage:
- administered once every 4 weeks via IV infusion
Adverse effects:
- hypersensitivity reactions
- most common adverse effects in clinical trials
- anaphylaxis
- cancer
- myalgia
Mechanism of action:
- recombinant humanized IL5 monoclonal antibody (antagonist)
- reduces blood eosinophils
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
recombinant protein; chimer
antiasthmatic agent
References
- FDA News Release. March 23, 2016
FDA approves Cinqair to treat severe asthma
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491980.htm